Oculis Holding AG (NASDAQ:OCS - Get Free Report)'s share price rose 4% during mid-day trading on Thursday . The company traded as high as $19.34 and last traded at $19.49. Approximately 34,697 shares changed hands during mid-day trading, a decline of 24% from the average daily volume of 45,579 shares. The stock had previously closed at $18.74.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. HC Wainwright decreased their price target on Oculis from $30.00 to $29.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. Chardan Capital reiterated a "buy" rating and issued a $28.00 target price on shares of Oculis in a research report on Thursday, March 13th. Finally, Robert W. Baird boosted their target price on shares of Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research note on Thursday, March 13th.
Read Our Latest Stock Analysis on OCS
Oculis Trading Up 0.2 %
The firm has a market cap of $856.21 million, a P/E ratio of -10.16 and a beta of 0.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm has a fifty day moving average of $20.95 and a 200-day moving average of $17.26.
Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. Equities research analysts forecast that Oculis Holding AG will post -2.09 earnings per share for the current year.
Institutional Investors Weigh In On Oculis
A number of hedge funds have recently made changes to their positions in OCS. Bellevue Group AG bought a new stake in Oculis during the 4th quarter valued at $170,000. XTX Topco Ltd acquired a new stake in Oculis in the fourth quarter worth approximately $225,000. Geode Capital Management LLC boosted its stake in Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after purchasing an additional 1,800 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Oculis in the 4th quarter worth $389,000. Finally, Bank of America Corp DE lifted its holdings in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after buying an additional 10,667 shares during the period. Institutional investors own 22.30% of the company's stock.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Further Reading
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
